News Acquisitive Ipsen builds again with $952m Albireo buy French drugmaker Ipsen has continued a recent spate of deal-making with a $42-per-share offer to buy US biotech Albireo and its rare disease therapy Bylvay.
Views & Analysis Q&A: Albireo’s Ron Cooper on bile acid modulation While bile acids might not be as trendy as gene editing, modulating them has potential for first-in-class therapies for liver diseases.
News Consolidation in psychedelics as atai pairs with Beckley Beckley Psytech has agreed to merge with atai Life Sciences in a deal that would bring together two psychedelic medicine pioneers.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.